Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Retained Earnings (2020 - 2025)

Mainz Biomed's Retained Earnings history spans 5 years, with the latest figure at $27.6 million for Q4 2024.

  • For Q4 2024, Retained Earnings rose 29.64% year-over-year to $27.6 million; the TTM value through Dec 2024 reached $27.6 million, up 29.64%, while the annual FY2024 figure was $27.6 million, 29.64% up from the prior year.
  • Retained Earnings for Q4 2024 was $27.6 million at Mainz Biomed, up from $21.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $27.6 million in Q4 2024 and bottomed at -$202490.0 in Q4 2020.
  • The 5-year median for Retained Earnings is $9.7 million (2021), against an average of $11.7 million.
  • The largest annual shift saw Retained Earnings tumbled 99.46% in 2022 before it soared 40692.26% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$202490.0 in 2020, then soared by 4908.17% to $9.7 million in 2021, then crashed by 99.46% to $52182.0 in 2022, then skyrocketed by 40692.26% to $21.3 million in 2023, then rose by 29.64% to $27.6 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Retained Earnings are $27.6 million (Q4 2024), $21.3 million (Q4 2023), and $52182.0 (Q4 2022).